US20210401709A1 - Process for depigmenting keratin materials using thiopyridinone compounds - Google Patents

Process for depigmenting keratin materials using thiopyridinone compounds Download PDF

Info

Publication number
US20210401709A1
US20210401709A1 US17/340,594 US202117340594A US2021401709A1 US 20210401709 A1 US20210401709 A1 US 20210401709A1 US 202117340594 A US202117340594 A US 202117340594A US 2021401709 A1 US2021401709 A1 US 2021401709A1
Authority
US
United States
Prior art keywords
acid
optionally substituted
group
chosen
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/340,594
Inventor
Xavier Marat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to US17/340,594 priority Critical patent/US20210401709A1/en
Publication of US20210401709A1 publication Critical patent/US20210401709A1/en
Assigned to L'OREAL reassignment L'OREAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARAT, XAVIER
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Definitions

  • R 2 denotes a saturated linear C 1 -C 10 or branched C 3 -C 10 or cyclic C 5 -C 6 alkyl hydrocarbon-based group, optionally interrupted with an oxygen atom and/or optionally containing a —CONH 2 group and/or optionally substituted with a hydroxyl group; a phenyl group; or a saturated C 1 -C 5 alkyl group substituted with a phenyl radical itself optionally substituted with one or more hydroxyl or C 1 -C 3 alkoxy radicals;
  • R 1 denotes a hydrogen atom and R 2 denotes a radical chosen from:
  • physiologically acceptable medium is understood to mean a medium that is compatible with keratin materials of human beings, such as the skin of the body or of the face, the lips, the mucous membranes, the eyelashes, the nails, the scalp and/or the hair.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Cosmetics (AREA)

Abstract

The invention relates to a cosmetic process for depigmenting, lightening and/or whitening keratin materials, in particular the skin, which comprises the application of a cosmetic composition comprising a compound of formula (I):
Figure US20210401709A1-20211230-C00001
  • or its tautomer form of formula (I′):
Figure US20210401709A1-20211230-C00002
  • in which:
  • R1 and R2, which may be identical or different, denote a radical chosen from:
  • a) a hydrogen atom;
  • b) a C1-C20 alkyl group optionally interrupted with N, S or O, optionally substituted with one or more group(s) chosen from -—OR3, —SR3, —NR3R4, —CONHR3; —COORS; and an aryl group optionally substituted with one or more hydroxyls and/or with one or more C1-C8 alkoxy radicals;
  • c) a C1-C8 alkyl group substituted with a C5-C12 aryl radical optionally substituted with one or more hydroxyls and/or with one or more C1-C8 alkoxy radicals;
  • d) a phenyl group optionally substituted with one or more hydroxyls and/or with one or more C1-C8 alkoxy radicals;
  • R3 denoting H or a C1-C5 alkyl group,
  • R4 denoting H, a C1-C5 hydrocarbon-based group or an acetyl group;
  • it being possible for R1 and R2 to form, with the nitrogen atom which bears them, a ring chosen from pyrrolidine, pyrroline, piperidine, piperazine, morpholine, thiomorpholine and azepine.
The invention also relates to the cosmetic use of a compound (I) or (I′) as a whitening, lightening and/or depigmenting agent for keratin materials.

Description

  • This application is a Continuation of U.S. Ser. No. 14/804,531, filed Jul. 21, 2015, which is a Divisional of U.S. application Ser. No. 13/994,457, filed on Aug. 8, 2013, now U.S. Pat. No. 9,138,392, which is a National Stage of Application PCT/EP2011/072180, filed on Dec. 8, 2011, which claims the benefit of priority from U.S. Provisional Application No. 61/425,258, filed Dec. 21, 2010, the entire contents of which are hereby incorporated by reference.
  • The present invention relates to a cosmetic treatment process in particular for depigmenting and/or whitening the skin, that employs at least one compound of thiopyridinone type.
  • At various periods in their life, certain people develop darker and/or more coloured marks on their skin, and more especially on the hands, which gives the skin a heterogeneous appearance. These marks are due in particular to a high concentration of melanin in the keratinocytes located at the surface of the skin.
  • The use of harmless topical depigmenting substances which exhibit good efficacy is especially desirable with a view to treating pigmentary marks.
  • The mechanism of formation of skin pigmentation, i.e. of the formation of melanin, is particularly complex and involves, schematically, the following principal steps:
  • Tyrosine - - - >Dopa - - - >Dopaquinone - - - >Dopachrome - - - >Melanin
  • Tyrosinase (monophenol dihydroxyl phenylalanine: oxygen oxidoreductase EC 1.14.18.1) is the essential enzyme involved in this series of reactions. It catalyzes in particular the reaction converting tyrosine to Dopa (dihydroxyphenylalanine) by virtue of its hydroxylase activity, and the reaction converting Dopa to dopaquinone by virtue of its oxidase activity. This tyrosinase acts only when it is in the mature form, under the action of certain biological factors.
  • A substance is acknowledged to be depigmenting if it acts directly on the vitality of epidermal melanocytes, where melanogenesis takes place, and/or if it interferes with one of the steps of melanin biosynthesis, either by inhibiting one of the enzymes involved in melanogenesis, or by being inserted as a structural analogue of one of the chemical compounds of the melanin synthesis chain, which chain may then be blocked and thus ensure depigmentation.
  • Arbutin, niacinamide and kojic acid are known as skin depigmenting agents.
  • Substances have been sought which exhibit an effective depigmenting action, in particular greater than that of arbutin, niacinamide and kojic acid.
  • In this regard, the applicant has found, surprisingly and unexpectedly, that certain thiopyridinone compounds exhibit good depigmenting activity, even at low concentration.
  • The subject of the invention is therefore a nontherapeutic cosmetic process for depigmenting, lightening and/or whitening keratin materials, in particular the skin, which comprises the application of a cosmetic composition comprising, in a physiologically acceptable medium, at least one compound of formula (I) as defined hereinafter.
  • The invention also relates to the nontherapeutic cosmetic use of a compound of formula (I) as a whitening, lightening and/or depigmenting agent for keratin materials, in particular the skin.
  • The compounds used according to the invention allow effective depigmenting and/or lightening, or even whitening, of the skin of human beings. They are in particular intended to be applied to the skin of individuals exhibiting brownish pigmentation marks or senescence marks, or to the skin of individuals who wish to combat the appearance of a brownish colour arising from melanogenesis.
  • They may also allow depigmentation and/or lightening of body hair, the eyelashes, head hair and also the lips and/or the nails.
  • The compounds used according to the invention therefore correspond to formula (I) or (I′) below:
  • Figure US20210401709A1-20211230-C00003
  • in which:
  • R1 and R2, which may be identical or different, denote a radical chosen from:
      • a) a hydrogen atom;
      • b) a saturated linear C1-C20 or branched C3-C20 or unsaturated C2-C20 alkyl group, optionally interrupted with one or more heteroatoms chosen from N, S and O, and/or optionally substituted with one or more groups, which may be identical or different, chosen from:
        • i) —OR3
        • ii) —SR3,
        • iii) —NR3R4
        • iv) —CONHR3
        • v) —COOR3;
        • vi) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more C1-C8 alkoxy radicals;
      • c) a saturated C1-C8 alkyl group substituted with a C5-C12 aryl radical optionally substituted with one or more hydroxyls and/or with one or more C1-C8 alkoxy radicals;
      • d) a phenyl group optionally substituted with one or more hydroxyls and/or with one or more C1-C8 alkoxy radicals;
  • R3 denoting a hydrogen atom or a saturated linear C1-C5 or branched C3-C5 or unsaturated C2-C5 hydrocarbon-based group,
  • R4 denoting a hydrogen atom; a saturated linear C1-C5 or branched C3-C5 hydrocarbon-based group; or an acetyl group;
  • it being possible for R1 and R2 to form, with the nitrogen atom which bears them, a ring chosen from pyrrolidine, pyrroline, piperidine, piperazine, morpholine, thiomorpholine and azepine;
  • and also the salts thereof, the solvates thereof and the optical isomers thereof, and the racemates thereof.
  • The compound (I′) is the tautomer form of the compound (I) when a tautomeric equilibrium exists according to the following scheme:
  • Figure US20210401709A1-20211230-C00004
  • The salts of the compounds of formula (I) or (I′) comprise the conventional nontoxic salts of said compounds, such as those formed from acid or from base.
  • As salts of the compound of formula (I) or (I′), when it comprises a quaternizable nitrogen atom), mention may be made of:
  • a) the salts obtained by addition of the compound (I) or (I′) with an inorganic acid, in particular chosen from hydrochloric acid, boric acid, hydrobromic acid, hydrioic acid, sulphuric acid, nitric acid, carbonic acid, phosphoric acid and tetrafluoroboric acid;
  • b) or the salts obtained by addition of the compound (I) or (I′) with an organic acid, in particular chosen from acetic acid, propionic acid, succinic acid, fumaric acid, lactic acid, glycolic acid, citric acid, gluconic acid, salicylic acid, tartaric acid, terephthalic acid, methylsulphonic acid, ethylsulphonic acid, benzenesulphonic acid, toluenesulphonic acid and triflic acid.
  • Mention may also be made of the salts obtained by addition of the compound of formula (I) or (I′) (when it comprises an acid group) with an inorganic base, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, magnesium hydroxide, lithium hydroxide, and sodium, potassium or calcium carbonates or hydrogen carbonates, for example;
  • or with an organic base, such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine. This primary, secondary or tertiary alkylamine may comprise one or more nitrogen and/or oxygen atoms and may therefore comprise, for example, one or more alcohol functions; mention may in particular be made of 2-am ino-2-methylpropanol, ethanolamine, triethanolamine, 2-dimethylaminopropanol, 2-amino-2-(hydroxymethyl)-1,3-propanediol and 3-(dimethylamino)propylamine.
  • Mention may also be made of amino acids such as, for example, lysine, arginine, guanidine, glutamic acid or aspartic acid.
  • Advantageously, the salts of the compounds of formula (I) or (I′) (when it comprises an acid group) may be chosen from alkali metal salts or alkaline earth metal salts, such as sodium, potassium, calcium or magnesium salts; and ammonium salts.
  • Advantageously, the salts of the compounds of formula (I) or (I′) (when it comprises a quaternizable nitrogen atom) can be chosen from halides such as chloride or bromide; and citrates, acetates, succinates, phosphates, lactates and tartrates.
  • The acceptable solvates of the compounds described in the present invention comprise conventional solvates such as those formed during the preparation of said compounds as a result of the presence of solvents. By way of example, mention may be made of the solvates resulting from the presence of water or of linear or branched alcohols such as ethanol or isopropanol.
  • The optical isomers are in particular enantiomers and diastereoisomers.
  • Preferentially, the linear or branched groups can be chosen from: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl and eicosyl.
  • More preferentially, the saturated linear or branched alkyl groups can be chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl and octyl.
  • Preferentially, the C1-C4 alkoxy groups can be chosen from methoxy, ethoxy, propoxy and butoxy, and even more preferentially methoxy.
  • The compounds of formula (I) can be obtained, in a known manner, by reacting 2-mercaptonicotinic acid and an amine of formula HNR1R2 (R1 and R2 having the meanings described above), in particular in the presence of a base such as carbonyldiim idazole.
  • The compounds of formula (I) can also be obtained, in a known manner, by reacting 2-mercaptonicotinic acid or 2-chloronicotinic acid with an amine of formula HNR1R2 (R1 and R2 having the meanings described above), in particular in the presence of an agent for activating carboxylic acids according to the conventional methods for activating acids (described, for example, in Comprehensive Organic Transformation by R. Larock, published by Wiley VCH, in the chapter Interconversion of nitriles, carboxylic acids and derivatives). Use is preferably made of an agent for activating carboxylic acids which makes it possible to form an acid chloride (for example, using thionyl chloride or oxalyl chloride, or 1-chloro-N,N,2-trimethyl-1-propenamine) or to form a mixed anhydride (using alkyl chloroformates), or carbodiimides or diethyl cyanophosphate are used to form carbamimidates or acylphosphonates (Phosphorus in organic synthesis-XI, Amino acids and peptides-XXI, Reaction of diethyl phosphorocyanidate with carboxylic acids. A new synthesis of carboxylic esters and amides, Tetrahedron, 32, 1976, 2211-2217).
  • When 2-chloronicotinic acid is used as starting reagent, the chloroamide obtained is then used in an exchange reaction between chlorine and sulphur by means of reagents such as NaSH, thiourea, sodium thiosulphate or thioacetic acid (in basic medium).
  • Compounds of formula (I) or (I′) are described in the following documents:
  • EP-A-298752, WO03/014062, EP-A-298752, FR-A-2349591, EP-A-2555450, WO 03/014062 and WO 2008/012532, and in the publications
      • article A. Monge, V. Martinez-Merino; Synthesis of 2-substituted 3-Oxoisothiazolo[5,4-b]pyridines; J. heterocyclic. Chem, 22, 1353 (1985).
      • article A. Dunn, R. Norrie; Synthesis of pyrido-1,3-thiazines; Zeitschrift fur chemie 1988, vol 28, n° 6, p 212/214.
      • S. Andreae; J. Parkt. Chem. 339 (1997) 152-158;
      • S. Gorsuch; Biorganic & Medicinal Chemistry 17(2009) 467-474.
      • A. Monge et al; J. Heterocyclic Che. 25, 23 (1988).
      • M. Pregnolato; II Farmaco 55 (2000) 669-679.
  • Preferably, the compounds of the formula (I) or (I′) have the following meanings:
  • R1 denotes a radical chosen from:
      • a) a hydrogen atom;
      • b) a saturated linear C1-C10 or branched C3-C10 or unsaturated C2-C10 alkyl group, optionally substituted with one or more OR3 groups;
  • R2 denotes a radical chosen from:
      • a) a saturated linear C1-C10 or branched C3-C10 or cyclic C3-C7 alkyl group, optionally interrupted with one or more oxygen atoms, preferably one, and/or optionally containing one or more groups, which may be identical or different, chosen from:
        • i) —OR3,
        • ii) —NR3R4,
        • iii) —CONHR3,
        • iv) —COOR3
      • b) a phenyl group optionally substituted with one or more hydroxyls and/or with one or more C1-C3 alkoxy radicals;
      • c) a saturated C1-C5 alkyl group substituted with a phenyl radical optionally substituted with one or more hydroxyls or with one or more C1-C3 alkoxy radicals;
  • R3 denoting a hydrogen atom or a saturated linear C1-C5 or branched C3-C5 hydrocarbon-based group;
  • R4 denoting a hydrogen atom or a saturated linear C1-C5 or branched C3-C5 hydrocarbon-based group;
  • and the salts thereof, the solvates thereof and the optical isomers thereof, and the racemates thereof.
  • Preferentially, the compounds of formula (I) or (I′) have the following meanings:
  • R1 denotes a hydrogen atom or a linear C1-C4 alkyl radical optionally substituted with one or more hydroxyl groups;
  • R2 denotes a radical chosen from:
      • a) a saturated linear C1-C10 or branched C3-C10 or cyclic C5-C7 alkyl group, optionally interrupted with an oxygen atom and/or optionally containing a —CONH2 group and/or optionally substituted with one or more hydroxyl groups;
      • b) a phenyl group;
      • c) a saturated C1-C5 alkyl group substituted with a phenyl radical optionally substituted with one or more hydroxyl or C1-C3 alkoxy radicals;
  • and also the salts thereof, the solvates thereof and the optical isomers thereof, and the racemates thereof.
  • More preferentially, the compounds of formula (I) or (I′) have the following meanings:
  • R1 denotes a hydrogen atom or a C1-C4 hydroxyalkyl group;
  • R2 denotes a saturated linear C1-C10 or branched C3-C10 or cyclic C5-C6 alkyl hydrocarbon-based group, optionally interrupted with an oxygen atom and/or optionally containing a —CONH2 group and/or optionally substituted with a hydroxyl group; a phenyl group; or a saturated C1-C5 alkyl group substituted with a phenyl radical itself optionally substituted with one or more hydroxyl or C1-C3 alkoxy radicals;
  • and also the salts thereof, the solvates thereof and the optical isomers thereof, and the racemates thereof.
  • The subject of the invention is also the novel compounds of formulae (Ia) and (Ia′) corresponding to those of formula (I) or (I′)
  • in which:
      • when R1 denotes a hydrogen atom, then R2 denotes a radical chosen from unsaturated C2-C20 alkyls, cyclic C7 alkyl radicals, saturated linear C1-C20 or branched C3-C20 alkyls, substituted with one or more identical or different —OR3 groups, and (C1-C20)alkylaryls substituted with one or more identical or different —OR3 groups, R3 denoting a hydrogen atom or a saturated linear C1-C5 or branched C3-C5 or unsaturated C2-C5 hydrocarbon-based group;
      • when R1 denotes a saturated linear C1-C10 or branched C3-C10 or unsaturated C2-C10 alkyl group, optionally substituted with one or more —OR3 groups, then R2 denotes a radical chosen from:
  • a) a saturated branched C3-C12 or cyclic C3-C7 alkyl group, optionally interrupted with one or more oxygen atoms, preferably one, and/or optionally containing one or more identical or different —OR3 groups,
  • R3 denoting a hydrogen atom or an optionally hydroxylated, saturated linear C1-C5 or branched C3-C5 hydrocarbon-based group;
  • and also the salts thereof, the optical isomers thereof and the racemates thereof.
  • Preferably, for the novel compounds of the formulae (Ia) and (Ia′):
      • when R1 denotes a hydrogen atom, then R2 denotes a radical chosen from unsaturated C2-C20 alkyls, saturated linear C1-C20 or branched C3-C20 alkyls, substituted with one or more identical or different —OR3 groups, and (C1-C6)alkylphenyls substituted with one or more identical or different —OR3 groups, R3 denoting a hydrogen atom or a saturated linear C1-C5 or branched C3-C5 or unsaturated C2-C5 hydrocarbon-based group;
      • when R1 denotes a saturated linear C1-C12 or branched C3-C10 or unsaturated C2-C10 alkyl group, optionally substituted with one or more —OR3 groups, then R2 denotes a radical chosen from:
  • a) a saturated branched C3-C12 or cyclic C3-C7 alkyl group, optionally interrupted with one or more oxygen atoms, preferably one, and/or optionally containing one or more identical or different —OR3 groups,
  • R3 denoting a hydrogen atom or an optionally hydroxylated, saturated linear C1-C5 or branched C3-C5 hydrocarbon-based group,
  • and also the salts thereof, the optical isomers thereof and the racemates thereof.
  • Preferably, for the novel compounds of formulae (Ia) and (Ia′):
      • when R1 denotes a hydrogen atom, then R2 denotes a radical chosen from saturated linear C1-C20 or branched C3-C20 alkyls, substituted with one or more identical or different —OR3 groups, and (C1-C6)alkylphenyls substituted with one or more identical or different —OR3 groups, R3 denoting a hydrogen atom or a saturated linear C1-C5 or branched C3-C5 or unsaturated C2-C5 hydrocarbon-based group;
      • when R1 denotes a saturated linear C1-C10 or branched C3-C10 or unsaturated C2-C10 alkyl group, optionally substituted with one or more —OR3 groups, then R2 denotes a radical chosen from:
  • a) a saturated branched C3-C12 or cyclic C3-C7 alkyl group, optionally interrupted with one or more oxygen atoms, preferably one, and/or optionally containing one or more identical or different —OR3 groups,
  • R3 denoting a hydrogen atom or an optionally hydroxylated, saturated linear C1-C5 or branched C3-C5 hydrocarbon-based group.
  • Preferably, for the novel compounds of formulae (Ia) and (Ia′):
  • R1 denotes a hydrogen atom and R2 denotes a radical chosen from:
  • a) a saturated linear C1-C10 or branched C3-C10 or cyclic C5-C7 alkyl group, substituted with one or more hydroxyl groups, and optionally interrupted with an oxygen atom, or
  • R1 denotes a linear C1-C4 alkyl radical optionally substituted with one or more hydroxyl groups; and R2 denotes a radical chosen from:
  • a) a saturated linear C1-C10 or branched C3-C10 or cyclic C5-C7 alkyl group, substituted with one or more hydroxyl groups, and optionally interrupted with an oxygen atom.
  • Preferentially, for the novel compounds of formulae (Ia) and (Ia′):
  • R1 denotes a hydrogen atom and R2 denotes a saturated linear C1-C10 or branched C3-C10 or cyclic C5-C6 alkyl hydrocarbon-based group, optionally interrupted with an oxygen atom and optionally substituted with a hydroxyl group, or
  • R1 denotes a C1-C4 hydroxyalkyl group;
  • R2 denotes a saturated linear C1-C10 or branched C3-C10 or cyclic C5-C6 alkyl hydrocarbon-based group, optionally interrupted with an oxygen atom and optionally substituted with a hydroxyl group.
  • Among the compounds of formula (I), the following compounds are preferably used:
  • No. Structure Chemical name CAS No.
    1
    Figure US20210401709A1-20211230-C00005
         		N-methyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 91859-74-4
    2
    Figure US20210401709A1-20211230-C00006
         		N-ethyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 91859-75-5
    3
    Figure US20210401709A1-20211230-C00007
         		N-isopropyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 91859-76-6
    4
    Figure US20210401709A1-20211230-C00008
         		N-propyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 330667-56-6
    5
    Figure US20210401709A1-20211230-C00009
         		N-(2-methylpropyl)-2- thioxo-1,2- dihydropyridine-3- carboxamide 1100027-79-9
    6
    Figure US20210401709A1-20211230-C00010
         		N-butyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 65282-55-5
    7
    Figure US20210401709A1-20211230-C00011
         		N-pentyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 330667-57-7
    8
    Figure US20210401709A1-20211230-C00012
         		N-octyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 91859-77-7
    9
    Figure US20210401709A1-20211230-C00013
         		N-nonyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 1031149-44-6
    10
    Figure US20210401709A1-20211230-C00014
         		N,N-dimethyl-2- mercaptonicotinamide 121650-19-9
    11
    Figure US20210401709A1-20211230-C00015
         		N-cyclopentyl-2-thioxo- 1,2-dihydropyridine-3- carboxamide 1099928-42-3
    12
    Figure US20210401709A1-20211230-C00016
         		N-cyclohexyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 91859-78-8
    13
    Figure US20210401709A1-20211230-C00017
         		N-cycloheptyl-2-thioxo- 1,2-dihydropyridine-3- carboxamide 451473-73-7
    14
    Figure US20210401709A1-20211230-C00018
         		N-phenyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 104857-16-1
    15
    Figure US20210401709A1-20211230-C00019
         		N-benzyl-2-thioxo-1,2- dihydropyridine-3- carboxamide 91859-79-9
    16
    Figure US20210401709A1-20211230-C00020
         		N-[2-(4- methoxyphenyl)ethyl]-2- thioxo-1,2- dihydropyridine-3- carboxamide 923682-88-6
    17
    Figure US20210401709A1-20211230-C00021
         		N-(3-ethoxypropyl)-2- thioxo-1,2- dihydropyridine-3- carboxamide 1061763-97-02
    18
    Figure US20210401709A1-20211230-C00022
         		N-(2-amino-2-oxoethyl)-2- thioxo-1,2- dihydropyridine-3- carboxamide 497262-18-7
    19
    Figure US20210401709A1-20211230-C00023
         		N-(2-hydroxyethyl)-2- thioxo-1,2- dihydropyridine-3- carboxamide
    20
    Figure US20210401709A1-20211230-C00024
         		N,N-bis(2-hydroxyethyl)- 2-thioxo-1,2- dihydropyridine-3- carboxamide
    21
    Figure US20210401709A1-20211230-C00025
         		N-(2,3-dihydroxypropyl)- 2-thioxo-1,2- dihydropyridine-3- carboxamide
    22
    Figure US20210401709A1-20211230-C00026
         		N-(1,3-dihydroxypropan- 2-yl)-2-thioxo-1,2- dihydropyridine-3- carboxamide
    23
    Figure US20210401709A1-20211230-C00027
         		N-ethyl-N-(2- hydroxyethyl)-2-thioxo- 1,2-dihydropyridine-3- carboxamide
    24
    Figure US20210401709A1-20211230-C00028
         		N-(3-hydroxypropyl)-2- thioxo-1,2- dihydropyridine-3- carboxamide
    25
    Figure US20210401709A1-20211230-C00029
         		N-[2-(2- hydroxyethoxy)ethyl]-2- thioxo-1,2- dihydropyridine-3- carboxamide
    26
    Figure US20210401709A1-20211230-C00030
         		N-(3-methoxypropyl)-2- thioxo-1,2- dihydropyridine-3- carboxamide
    27
    Figure US20210401709A1-20211230-C00031
         		N.N-diethyl 2- mercaptonicotinamide 121050-20-2
    28
    Figure US20210401709A1-20211230-C00032
         		Ethyl N-[(2-thioxo-1,2- dihydropyridin-3- yl)carbonyl]alaninate
    29
    Figure US20210401709A1-20211230-C00033
         		Ethyl N-[(2-thioxo-1,2- dihydropyridin-3- yl)carbonyl]phenyl alaninate
    30
    Figure US20210401709A1-20211230-C00034
         		N-[2- (dimethylamino)ethyl]-N- ethyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
  • Among these compounds, the following compounds are more particularly preferred:
  • No. Structure Chemical name
    1
    Figure US20210401709A1-20211230-C00035
         		N-methyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    2
    Figure US20210401709A1-20211230-C00036
         		N-ethyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    3
    Figure US20210401709A1-20211230-C00037
         		N-isopropyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    4
    Figure US20210401709A1-20211230-C00038
         		N-propyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    5
    Figure US20210401709A1-20211230-C00039
         		N-(2-methylpropyl)-2- thioxo-1,2-dihydropyridine- 3-carboxamide
    6
    Figure US20210401709A1-20211230-C00040
         		N-butyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    7
    Figure US20210401709A1-20211230-C00041
         		N-pentyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    11
    Figure US20210401709A1-20211230-C00042
         		N-cyclopentyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    12
    Figure US20210401709A1-20211230-C00043
         		N-cyclohexyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    13
    Figure US20210401709A1-20211230-C00044
         		N-cycloheptyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    15
    Figure US20210401709A1-20211230-C00045
         		N-benzyl-2-thioxo-1,2- dihydropyridine-3- carboxamide
    16
    Figure US20210401709A1-20211230-C00046
         		N-[2-(4- methoxyphenyl)ethyl]-2- thioxo-1,2-dihydropyridine- 3-carboxamide
    19
    Figure US20210401709A1-20211230-C00047
         		N-(2-hydroxyethyl)-2- thioxo-1,2-dihydropyridine- 3-carboxamide
    20
    Figure US20210401709A1-20211230-C00048
         		N,N-bis(2-hydroxyethyl)-2- thioxo-1,2-dihydropyridine- 3-carboxamide
    21
    Figure US20210401709A1-20211230-C00049
         		N-(2,3-dihydroxypropyl)-2- thioxo-1,2-dihydropyridine- 3-carboxamide
    23
    Figure US20210401709A1-20211230-C00050
         		N-ethyl-N-(2-hydroxyethyl)- 2-thioxo-1,2- dihydropyridine-3- carboxamide
    27
    Figure US20210401709A1-20211230-C00051
         		N,N-diethyl 2- mercaptonicotinamide

    and also the salts thereof, the optical isomers thereof and the solvates thereof.
  • Compounds 1 and 10 are described in application EP-A-298752 as synthesis intermediates.
  • Compounds 2 to 8, 11 and 12 are described in FR-A-2555450.
  • Compound 14 is described in the article A. Monge, V. Martinez-Merino; Synthesis of 2-substituted 3-Oxoisothiazolo[5,4-b]pyridines; J. heterocyclic. Chem, 22, 1353 (1985).
  • Compounds 4, 6, 7 and 15 are described in the article A. Dunn, R. Norrie; Synthesis of pyrido-1,3-thiazines; Zeitschrift fur chemie 1988, vol 28, n° 6, p 212/214.
  • Compound 14 is described in the article A. Monge, V. Martinez-Merino; Synthesis of 2-substituted 3-Oxoisothiazolo[5,4-b]pyridines; J. heterocyclic. Chem, 22, 1353 (1985).
  • Compound 18 is described in WO-A-03/014062.
  • Compound 27 is described in EP 298752.
  • Compounds 2, 7, 12, 16, 21 and 27 are the most particularly preferred.
  • The compounds of formula (I) and/or (I′) according to the invention are of quite particular use in the cosmetics field.
  • The composition used according to the invention comprises a compound of formula (I) and/or (I′) as described above, in a physiologically acceptable medium.
  • The compound (I) and/or (I′) can be present in the composition used according to the invention in an amount which can be between 0.01 and 10% by weight, preferably between 0.1 and 5% by weight, in particular from 0.5 to 3% by weight, relative to the total weight of the composition.
  • The term “physiologically acceptable medium” is understood to mean a medium that is compatible with keratin materials of human beings, such as the skin of the body or of the face, the lips, the mucous membranes, the eyelashes, the nails, the scalp and/or the hair.
  • The composition used according to the invention may thus comprise all the adjuvants which are commonly employed in the cosmetics field.
  • Mention may in particular be made of water; organic solvents, in particular C2-C6 alcohols; oils, in particular hydrocarbon-based oils, silicone oils; waxes, pigments, fillers, dyes, surfactants, emulsifiers; cosmetic active agents, UV screens, polymers, thickeners, preservatives, fragrances, bactericides, odour absorbers and antioxidants.
  • These optional cosmetic adjuvants may be present in the composition in a proportion of from 0.001 to 80% by weight, in particular 0.1 to 40% by weight, relative to the total weight of the composition. In any event, these adjuvants, and also the proportions thereof, will be chosen by those skilled in the art in such a way that the advantageous properties of the compounds according to the invention are not, or not substantially, impaired by the envisaged addition.
  • As active agents, it will be advantageous to introduce into the composition used according to the invention at least one compound chosen from: desquamating agents; calmatives; organic or inorganic photoprotective agents, moisturizers; depigmenting or propigmenting agents; anti-glycation agents; NO-synthase inhibitors; agents for stimulating the synthesis of dermal or epidermal macromolecules and/or preventing degradation thereof; agents for stimulating fibroblast and/or keratinocyte proliferation or stimulating keratinocyte differentiation; muscle relaxants and/or dermo-decontracting agents; tensioning agents; anti-pollution agents and/or free-radical scavengers; agents that act on the microcirculation; agents that act on the energy metabolism of cells; and mixtures thereof.
  • Examples of such additional compounds are: retinol and derivatives thereof such as io retinyl palm itate; ascorbic acid and derivatives thereof such as magnesium ascorbyl phosphate and ascorbyl glucoside; tocopherol and derivatives thereof such as tocopheryl acetate; nicotinic acid and precursors thereof such as nicotinamide; ubiquinone; glutathione and precursors thereof such as L-2-oxothiazolidine-4-carboxylic acid; plant extracts and in particular plant proteins and hydrolysates thereof, and also plant hormones; marine extracts such as algal extracts; bacterial extracts; sapogenins such as diosgenin and wild yam extracts containing same; ceramides; hydroxy acids such as salicylic acid and 5-n-octanoylsalicylic acid; resveratrol; oligopeptides and pseudodipeptides and acyl derivatives thereof; manganese salts and magnesium salts, in particular the gluconates; and mixtures thereof.
  • The term “desquamating agent” is intended to mean any compound capable of acting:
      • either directly on desquamation by promoting exfoliation, such as β-hydroxy acids, in particular salicylic acid and derivatives thereof (including 5-n-octanoylsalicylic acid); α-hydroxy acids, such as glycolic acid, citric acid, lactic acid, tartaric acid, malic acid or mandelic acid; urea; gentisic acid; oligofucoses; cinnamic acid; Saphora japonica extract; resveratrol;
      • or on the enzymes involved in the desquamation or degradation of corneodesmosomes, glycosidases, stratum corneum chymotryptic enzyme (SCCE) or even other proteases (trypsin, chymotrypsin-like). Mention ay be made of agents for chelating mineral salts: EDTA; N-acyl-N,N′,N′-ethylenediaminetriacetic acid; am inosulphonic compounds and in particular (N-2 hydroxyethylpiperazine-N-2-ethane)sulphonic acid (HEPES); derivatives of 2-oxothiazolidine-4-carboxylic acid (procysteine); derivatives of alpha-amino acids of glycine type (as described in EP-0 852 949, and also sodium methyl glycine diacetate sold by BASF under the trade name Trilon M); honey; sugar derivatives such as O-octanoyl-6-D-maltose and N-acetylglucosamine.
  • The desquamating agents are generally present in the composition according to the invention in proportions ranging from 0.01 to 15% by weight, preferably ranging from 0.1 to 10% by weight, relative to the total weight of the composition.
  • As calmatives that can be used in the composition according to the invention, mention may be made of: pentacyclic triterpenes and extracts of plants (for example Glycyrrhiza glabra) containing them, for instance β-glycyrrhetinic acid and salts and/or derivatives thereof (glycyrrhetinic acid monoglucuronide, stearyl glycyrrhetinate, 3-stearoyloxyglycyrrhetic acid), ursolic acid and salts thereof, oleanolic acid and salts thereof, betulinic acid and salts thereof, an extract of Paeonia suffruticosa and/or lactiflora, salicylic acid salts and in particular zinc salicylate, phycosaccharides from the company Codif, an extract of Laminaria saccharina, canola oil, bisabolol and camomile extracts, allantoin, Sepivital EPC (phosphoric diester of vitamin E and C) from SEPPIC, omega-3 unsaturated oils such as musk rose oil, blackcurrant oil, ecchium oil, fish oil, plankton extracts, capryloylglycine, Seppicalm VG (sodium palmitoylproline and Nymphea alba) from SEPPIC, an extract of Pygeum, an extract of Boswellia serrata, an extract of Centipeda cunnighami, an extract of Helianthus annuus, an extract of Linum usitatissimum, tocotrienols, extracts of Cola nitida, piperonal, an extract of clove, an extract of Epilobium angustifolium, aloe vera, an extract of Bacopa moniera, phytosterols, cortisone, hydrocortisone, indomethacin and betamethasone.
  • The calmatives are generally present in the composition used according to the invention in proportions ranging from 0.01 to 15% by weight, preferably ranging from 0.1 to 10% by weight, relative to the total weight of the composition.
  • The organic photoprotective agents are in particular chosen from anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives, camphor derivatives; triazine derivatives such as those described in patent applications U.S. Pat. No. 4,367,390, EP863145, EP517104, EP570838, EP796851, EP775698, EP878469, EP933376, EP507691, EP507692, EP790243 and EP944624; benzophenone derivatives; β,β-diphenylacrylate derivatives; benzotriazole derivatives;
  • benzalmalonate derivatives; benzimidazole derivatives; imidazolines; bis-benzoazolyl derivatives as described in patents EP669323 and U.S. Pat. No. 2,463,264; p-aminobenzoic acid (PABA) derivatives; methylenebis(hydroxyphenylbenzotriazole) derivatives as described in applications U.S. Pat. Nos. 5,237,071, 5,166,355, GB2303549, DE19726184 and EP893119; screening polymers and screening silicones such as those described in particular in application WO-93/04665; and α-alkylstyrene-derived dimers such as those described in patent application DE 19855649.
  • The inorganic photoprotective agents can in particular be chosen from coated or uncoated metal oxide pigments or nanopigments (average size of the primary particles generally between 5 nm and 100 nm, preferably between 10 nm and 50 nm), for instance nanopigments of titanium oxide (amorphous or crystallized in rutile and/or anatase form), of iron oxide, of zinc oxide, of zirconium oxide or cerium oxide, which are all well-known UV photoprotective agents. Conventional coating agents are, moreover, alumina and/or aluminium stearate. Such coated or uncoated metal oxide nanopigments are in particular described in patent applications EP518772 and EP518773.
  • The photoprotective agents are generally present in the composition used according to the invention in proportions ranging from 0.1 to 20% by weight, preferably ranging from 0.2 to 15% by weight, relative to the total weight of the composition.
  • The composition used according to the invention may be in any of the galenical forms normally used in the cosmetics field, and in particular in the form of an optionally gelled aqueous or aqueous-alcoholic solution, a dispersion, optionally a two-phase dispersion, of the lotion type, an oil-in-water or water-in-oil or multiple (W/O/W or O/W/O) emulsion, an aqueous gel, a dispersion of oil in an aqueous phase by means of spherules, it being possible for these spherules to be polymeric nanoparticles such as nanospheres and nanocapsules or, better still, lipid vesicles of ionic and/or nonionic type; or aqueous or oily gels. These compositions are prepared according to the usual methods. According to this invention, a composition in the form of an emulsion, in particular an oil-in-water emulsion, is preferably used.
  • The composition used according to the invention may constitute a skincare composition, and in particular a cleansing, protecting, treatment or care cream for the face, for the hands, for the feet, for the major anatomical folds or for the body (for example, day creams, night creams, makeup-removing creams, foundation creams, antisun creams); a fluid foundation, a makeup-removing milk, a protective or care body milk or an antisun milk; a skincare lotion, gel or foam, such as a cleansing lotion.
  • The invention is illustrated in greater detail by the following nonlimiting examples.
    • EXAMPLES 1 to 4 Demonstration of the Activity on Constitutive Melanogenesis
  • A biological test demonstrated the depigmenting activity of 7 compounds of formula (I) (compounds 2, 7, 12, 16, 19, 21 and 27).
  • The modulatory effect of each compound on melanogenesis was measured according to the method described in FR-A-2734825 and also in the article by R. Schmidt, P. Krien and M. Régnier, Anal. Bichem., 235(2), 113-18,1996. This test is carried out on a coculture of keratinocytes and melanocytes.
  • For the compounds tested, the following were determined:
      • the cytotoxicity, by estimating leucine incorporation,
      • the inhibitory activity on melanin synthesis, by estimating the ratio of thiouracil incorporation to leucine incorporation, relative to 100% of the control (the control corresponds to the test carried out without test compound). The IC50 values (concentration for which 50% of the melanin synthesis is inhibited) were determined.
  • The test was also carried out with arbutin, niacinamide and kojic acid, which are known depigmenting compounds.
  • The results are collated in the following table:
  • Cytotoxicity on
    Compound coculture IC50
    Arbutin Non-cytotoxic Not attained
    (or greater
    than 500 μM)
    Kojic acid 100 μM Not attained
    (or greater
    than 500 μM)
    Niacinamide Non-cytotoxic Not attained
    Figure US20210401709A1-20211230-C00052
         		Non-cytotoxic 4.9 μM 
    Figure US20210401709A1-20211230-C00053
         		Non-cytotoxic 37 μM
    Figure US20210401709A1-20211230-C00054
         		100 μM 25 μM
    Figure US20210401709A1-20211230-C00055
         		Non-cytotoxic 32 μM
    Figure US20210401709A1-20211230-C00056
         		Non-cytotoxic 29 μM
    Figure US20210401709A1-20211230-C00057
         		Non-cytotoxic 410 μM 
    Figure US20210401709A1-20211230-C00058
         		Non-cytotoxic 128 μM 
  • Compounds 2, 7, 12, 16, 19, 21 and 27 therefore demonstrate their efficacy in inhibiting melanogenesis and are, moreover, more effective than arbutin, kojic acid and niacinamide.
  • Compound 2 is the most effective compound.
    • EXAMPLE 5
  • A depigmenting gel for the skin is prepared, comprising (% by weight):
  •
    Compound 2 2%
    Carbomer (Carbopol 981 from Lubrizol) 1%
    preservative qs
    water qs 100%   
  • When applied to the skin, the composition makes it possible to fade out brown marks.
  • A similar composition is prepared with compound 3 or compound 11 or compound 16.

Claims (1)

1. Nontherapeutic cosmetic process for depigmenting, lightening and/or whitening keratin materials, which comprises the application of a cosmetic composition comprising, in a physiologically acceptable medium, at least one compound of formula (I):
Figure US20210401709A1-20211230-C00059
or its tautomer form of formula (I′):
Figure US20210401709A1-20211230-C00060
in which:
R1 and R2, which may be identical or different, denote a radical chosen from:
a) a hydrogen atom;
b) a saturated linear C1-C20 or branched C3-C20 or unsaturated C2-C20 alkyl group, optionally interrupted with one or more heteroatoms chosen from N, S and O, and/or optionally substituted with one or more groups, which may be identical or different, chosen from:
i) —OR3
ii) —SR3,
iii) —NR3R4
iv) —CONHR3
v) —COOR3;
vi) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more C1-C8 alkoxy radicals;
c) a saturated C1-C8 alkyl group substituted with a C5-C12 aryl radical optionally substituted with one or more hydroxyls and/or with one or more C1-C8 alkoxy radicals;
d) a phenyl group optionally substituted with one or more hydroxyls and/or with one or more C1-C8 alkoxy radicals;
R3 denoting a hydrogen atom or a saturated linear C1-C5 or branched C3-C5 or unsaturated C2-C5 hydrocarbon-based group,
R4 denoting a hydrogen atom; a saturated linear C1-C5 or branched C3-C5 hydrocarbon-based group; or an acetyl group;
it being possible for R1 and R2 to form, with the nitrogen atom which bears them, a ring chosen from pyrrolidine, pyrroline, piperidine, piperazine, morpholine, thiomorpholine and azepine;
and also the salts thereof, the optical isomers thereof and the racemates thereof.
US17/340,594 2010-12-14 2021-06-07 Process for depigmenting keratin materials using thiopyridinone compounds Pending US20210401709A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/340,594 US20210401709A1 (en) 2010-12-14 2021-06-07 Process for depigmenting keratin materials using thiopyridinone compounds

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
FR1060474A FR2968661B1 (en) 2010-12-14 2010-12-14 PROCESS FOR DEPIGMENTING KERATINIC MATERIALS USING THIOPYRIDINONE COMPOUNDS
FR1060474 2010-12-14
US201061425258P 2010-12-21 2010-12-21
PCT/EP2011/072180 WO2012080075A1 (en) 2010-12-14 2011-12-08 Process for depigmenting keratin materials using thiopyridinone compounds
US201313994457A 2013-08-08 2013-08-08
US14/804,531 US11052028B2 (en) 2010-12-14 2015-07-21 Process for depigmenting keratin materials using thiopyridinone compounds
US17/340,594 US20210401709A1 (en) 2010-12-14 2021-06-07 Process for depigmenting keratin materials using thiopyridinone compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/804,531 Continuation US11052028B2 (en) 2010-12-14 2015-07-21 Process for depigmenting keratin materials using thiopyridinone compounds

Publications (1)

Publication Number Publication Date
US20210401709A1 true US20210401709A1 (en) 2021-12-30

Family

ID=43901581

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/994,457 Active US9138392B2 (en) 2010-12-14 2011-12-08 Process for depigmenting keratin materials using thiopyridinone compounds
US14/804,531 Active US11052028B2 (en) 2010-12-14 2015-07-21 Process for depigmenting keratin materials using thiopyridinone compounds
US17/340,594 Pending US20210401709A1 (en) 2010-12-14 2021-06-07 Process for depigmenting keratin materials using thiopyridinone compounds

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US13/994,457 Active US9138392B2 (en) 2010-12-14 2011-12-08 Process for depigmenting keratin materials using thiopyridinone compounds
US14/804,531 Active US11052028B2 (en) 2010-12-14 2015-07-21 Process for depigmenting keratin materials using thiopyridinone compounds

Country Status (7)

Country Link
US (3) US9138392B2 (en)
EP (1) EP2651897B1 (en)
JP (2) JP5931909B2 (en)
CN (3) CN116672278A (en)
ES (1) ES2792827T3 (en)
FR (1) FR2968661B1 (en)
WO (1) WO2012080075A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968661B1 (en) * 2010-12-14 2016-01-01 Oreal PROCESS FOR DEPIGMENTING KERATINIC MATERIALS USING THIOPYRIDINONE COMPOUNDS
FR3045604B1 (en) * 2015-12-18 2018-01-26 L'oreal PROCESS FOR DEPIGMENTING KERATINIC MATERIALS USING THIOPYRIDINONE COMPOUNDS
FR3073145B1 (en) * 2017-11-06 2020-05-22 L'oreal PROCESS FOR THE TREATMENT OF KERATINIC MATERIALS FROM DERIVATIVES OF ACIDIC C-GLYCOSIDES, ESTERS OR AMIDES, AND THE COSMETIC COMPOSITION CONTAINING THEM
FR3073144B1 (en) * 2017-11-06 2020-01-10 L'oreal PROCESS FOR THE TREATMENT OF KERATINIC MATERIALS FROM AMIDE C-GLYCOSIDE DERIVATIVES, AND THE COSMETIC COMPOSITION CONTAINING THEM
FR3115207B1 (en) 2020-10-15 2022-10-07 Oreal Use of thiopyridinone compounds to prevent the formation of cutaneous blackheads
EP4267098A1 (en) * 2020-12-22 2023-11-01 L'oreal Stabilization of thiopyridinone compound and yellowing reduction of composition comprising same
FR3118871B1 (en) * 2021-01-19 2024-03-01 Oreal stabilization of a thiopyridinone compound in a W/O type composition
US20240065960A1 (en) * 2020-12-22 2024-02-29 L'oreal Stabilization of thiopyridinone compound in w/o composition
FR3118877B1 (en) * 2021-01-18 2023-11-17 Oreal STABILIZATION OF A THIOPYRIDINONE COMPOUND AND REDUCTION OF YELLOWING OF THE COMPOSITION COMPRISING SAME
WO2023245459A1 (en) * 2022-06-21 2023-12-28 L'oreal Anti-oxidizing composition comprising a thiopyridinone compound
WO2023248248A1 (en) * 2022-06-21 2023-12-28 L'oréal Solubilization of thiopyridinone compound and composition comprising same
WO2023249912A1 (en) 2022-06-21 2023-12-28 L'oreal Cosmetic composition comprising hydrophilic antioxidants and thiopyridinone compounds
WO2023248247A1 (en) * 2022-06-21 2023-12-28 L'oréal Stabilization of thiopyridinone compound and composition comprising same
JP2024000769A (en) * 2022-06-21 2024-01-09 ロレアル Stabilization of thiopyridinone compound and composition comprising thiopyridinone compound
FR3139008A1 (en) 2022-08-24 2024-03-01 L'oreal SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING THE LATTER
WO2023245462A1 (en) 2022-06-21 2023-12-28 L'oreal Stabilized composition comprising thiopyridinone compound
WO2023249122A1 (en) * 2022-06-21 2023-12-28 L'oreal Stabilization of thiopyridinone compound and composition comprising same
FR3138869A1 (en) * 2022-08-22 2024-02-23 L'oreal STABILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING THE LATTER
WO2023245461A1 (en) * 2022-06-21 2023-12-28 L'oreal Composition for delivery of active compound
WO2023245463A1 (en) 2022-06-21 2023-12-28 L'oreal A stabilized composition comprising a thiopyridinone compound and chelating agent
US20230404882A1 (en) * 2022-06-21 2023-12-21 L'oreal Composition comprising compound of thiopyridinone type and polyglyceryl-based emulsifiers
FR3141621A1 (en) 2022-11-04 2024-05-10 L'oreal IMPROVING THE PHOTOSTABILITY OF THE THIOPYRIDINONE COMPOUND WITHOUT THE USE OF UV FILTERS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11052028B2 (en) * 2010-12-14 2021-07-06 L'oreal Process for depigmenting keratin materials using thiopyridinone compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2463264A (en) 1942-12-23 1949-03-01 Ciba Ltd Derivatives of cyclic amidines and process of making same
GB1560726A (en) * 1976-04-28 1980-02-06 Beecham Group Ltd Isothiazolo-pyridines
CH614878A5 (en) 1977-03-11 1979-12-28 Charmilles Sa Ateliers
LU84491A1 (en) * 1982-11-26 1984-06-13 Oreal ANTI-ACNE COMPOSITION CONTAINING AS AN ACTIVE COMPOUND A DERIVATIVE OF ISOTHIAZOLO- (5,4B) PYRIDINE ONE-3
FR2555450B1 (en) * 1983-11-24 1988-04-01 Oreal ANTI-ACNE COMPOSITION CONTAINING AS AN ACTIVE COMPOUND A DERIVATIVE OF ISOTHIAZOLO- (5,4B) PYRIDINE ONE-3
US5168113A (en) * 1987-07-10 1992-12-01 Takahiro Haga Mercapto-substituted pyridine compounds
JPH01216973A (en) * 1988-02-24 1989-08-30 Ishihara Sangyo Kaisha Ltd Production of substituted pyridine based compound
CA1301761C (en) * 1987-07-10 1992-05-26 Takahiro Haga Mercapto-substituted pyridine compounds and process for preparing the same
JPH01228908A (en) * 1988-03-10 1989-09-12 Sansho Seiyaku Co Ltd External medicine for inhibiting production of melamine
MY105600A (en) * 1988-08-04 1994-11-30 Ishihara Sangyo Kaisha Aminocarbonyl-substituted pyridinesulfinic acid or salts thereof
US5476852A (en) * 1989-05-03 1995-12-19 Janssen Pharmaceutica N.V. Method of topically treating acne vulgaris, hyperkeratotic dermatoses, and photo-aging of the skin
US5237071A (en) 1991-01-22 1993-08-17 Fairmount Chemical Company, Inc. Process for preparing 2,2'-methylene-bis(6-(2H-benzotriazol-2-yl)-4-hydrocarbyl phenols)
US5166355A (en) 1991-02-04 1992-11-24 Fairmount Chemical Co., Inc. Process for preparing substituted 2,2'-methylene-bis-[6-(2H-benzotriazol-2-yl)-4-hydrocarbyl-phenols]
FR2674850B1 (en) 1991-04-04 1993-07-02 Oreal S-TRIAZINIC DERIVATIVES CARRYING BENZALMALONATE SUBSTITUTES, FILTERING COSMETIC COMPOSITIONS CONTAINING THEM AND THEIR USE FOR PROTECTING THE SKIN AND HAIR FROM ULTRAVIOLET RADIATION.
FR2674851B1 (en) 1991-04-04 1995-02-10 Oreal S-TRIAZINIC DERIVATIVES CARRYING BENZYLIDENE CAMPHOR SUBSTITUENTS, FILTERING COSMETIC COMPOSITIONS AND THEIR USE FOR PROTECTING THE SKIN AND HAIR FROM ULTRAVIOLET RADIATION.
JPH05124924A (en) * 1991-04-09 1993-05-21 Sansho Seiyaku Co Ltd External preparation with melanin production-inhibitory activity
IT1247973B (en) 1991-06-04 1995-01-05 Sigma Prod Chim 1,3,5-TRIAZINE DERIVATIVES, THEIR PREPARATION AND USE AS SOLAR FILTERS
FR2677543B1 (en) 1991-06-13 1993-09-24 Oreal COSMETIC FILTERING COMPOSITION BASED ON BENZENE 1,4-DI ACID (3-METHYLIDENE-10-CAMPHOSULFONIC) AND NANOPIGMENTS OF METAL OXIDES.
FR2677544B1 (en) 1991-06-14 1993-09-24 Oreal COSMETIC COMPOSITION CONTAINING A MIXTURE OF NANOPIGMENTS OF METAL OXIDES AND MELANIC PIGMENTS.
FR2680683B1 (en) 1991-08-29 1993-11-12 Oreal COSMETIC FILTERING COMPOSITION CONTAINING A HYDROCARBON STRUCTURED FILTER POLYMER AND A FILTERED SILICONE.
IT1255729B (en) 1992-05-19 1995-11-15 Giuseppe Raspanti s-triazine derivatives as photostabilising agents
JPH06107531A (en) * 1992-09-28 1994-04-19 Kao Corp Cosmetic for fair skin and beauty
EP0669323B2 (en) 1994-02-24 2004-04-07 Haarmann & Reimer Gmbh Cosmetic and dermatological preparations, containing phenylene-1,4-bisbenzimidazole sulfonic acids
FR2734825B1 (en) 1995-05-31 1997-07-18 Oreal PROCESS FOR SEPARATING MELANIN FROM CELLS
GB9515048D0 (en) 1995-07-22 1995-09-20 Ciba Geigy Ag Sunscreen compositions
DE19543730A1 (en) 1995-11-23 1997-05-28 Ciba Geigy Ag Until resorcinyl-triazines
FR2744721B1 (en) 1996-02-12 1999-06-18 Oreal NOVEL INSOLUBLE S-TRIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND USES THEREOF
IT1283295B1 (en) 1996-03-22 1998-04-16 3V Sigma Spa SOLAR FILTERS
JP3510751B2 (en) * 1996-12-02 2004-03-29 カネボウ株式会社 Whitening cosmetics
FR2757163B1 (en) 1996-12-13 1999-02-05 Oreal NOVEL INSOLUBLE S-TRIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND USES THEREOF
EP0863145B1 (en) 1997-03-03 2003-10-01 F. Hoffmann-La Roche Ag Sunscreen compositions
TW508247B (en) 1997-03-31 2002-11-01 Shiseido Co Ltd Cosmetic or dermatological topical composition
EP0878469B1 (en) 1997-05-16 2004-10-27 Ciba SC Holding AG Resorcinyl-triazines
DE19726184A1 (en) 1997-06-20 1998-12-24 Beiersdorf Ag Oil-in-water or multiple emulsion with high concentration of suspended UVB filter
GB9715751D0 (en) 1997-07-26 1997-10-01 Ciba Geigy Ag Formulations
EP0933376B1 (en) 1998-01-02 2003-08-20 F. Hoffmann-La Roche Ag Silanyl-triazines as light screening compositions
DE19855649A1 (en) 1998-12-03 2000-06-08 Basf Ag Dimeric alpha-alkyl-styrene derivatives as photostable UV filters in cosmetic and pharmaceutical preparations
US6964949B2 (en) * 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
JP2002275159A (en) * 2001-03-16 2002-09-25 Japan Tobacco Inc Hcp inhibitor and compound having hcp inhibiting activity
EP1425262B1 (en) * 2001-08-03 2014-01-08 The Gov. of USA, as represented by the Secretary, Dept. of Health and Human services, National Institutes of Health Acylthiols and compositions thereof as anti-HIV and anti-retroviral agents
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
DE102007044277A1 (en) * 2007-09-17 2009-03-19 Grünenthal GmbH Substituted nicotinamide compounds and their use in medicines
TWI475020B (en) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11052028B2 (en) * 2010-12-14 2021-07-06 L'oreal Process for depigmenting keratin materials using thiopyridinone compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CH103 - Chapter 8: The Major Macromolecules [online]. Western Oregon University [retrieved on 10/26/2023]. Retrieved from the internet: <https://wou.edu/chemistry/chapter-11-introduction-major-macromolecules/#:~:text=11.1%20Introduction%3A%20The%20Four%20Major%20Macromolecules&text=These%20are%20>. (Year: 2023) *
Chalisova et al. Advances in Gerontology. Vol 5 No. 3, pp 176-179 (2015). (Year: 2015) *
Gvirtz et al. Pharmaceutics Vol 12, 299 (2020). (Year: 2020) *
Nilsson et al. Nature Vol 315, pages 61-63 (1895). (Year: 1985) *
The human proteome in skin [online]. The Human Protein Atlas [retrieved on 10/26/2023]. retrieved from the internet: <https://www.proteinatlas.org/humanproteome/tissue/skin#:~:text=Transcriptome>. (Year: 2023) *
Zhou et al. Frontiers in Endocrinology. Vol 14. (2023). (Year: 2023) *

Also Published As

Publication number Publication date
FR2968661B1 (en) 2016-01-01
WO2012080075A1 (en) 2012-06-21
FR2968661A1 (en) 2012-06-15
CN107411992A (en) 2017-12-01
EP2651897A1 (en) 2013-10-23
JP2014504289A (en) 2014-02-20
EP2651897B1 (en) 2020-04-01
JP2016074706A (en) 2016-05-12
JP6158276B2 (en) 2017-07-05
JP5931909B2 (en) 2016-06-08
CN103228630A (en) 2013-07-31
CN116672278A (en) 2023-09-01
US11052028B2 (en) 2021-07-06
US20130315847A1 (en) 2013-11-28
US20160045420A1 (en) 2016-02-18
US9138392B2 (en) 2015-09-22
ES2792827T3 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
US20210401709A1 (en) Process for depigmenting keratin materials using thiopyridinone compounds
EP3390363B1 (en) Process for depigmenting keratin materials using thiopyridinone compounds
EP2651886B1 (en) Method for depigmenting keratin materials using resorcinol derivatives
US8268805B2 (en) Use of ceramides for depigmenting the skin
US20070258921A1 (en) Process for depigmenting the skin
US8617524B2 (en) Depigmenting keratin materials utilizing dithiolane compounds
KR20040102354A (en) Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners
EP3509566B1 (en) Compounds for reducing cellular melanin content
JP2007536352A (en) Compositions comprising esters of ((dialkylamino) alkoxy) ethanol, in particular cosmetic compositions
US11389385B2 (en) Resorcinol derivatives for their cosmetic use

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: L'OREAL, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MARAT, XAVIER;REEL/FRAME:067283/0422

Effective date: 20130506